Trial · NCT07279688
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
NCT07279688, Phase 3, Recruiting, University Hospital, Brest
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica. Trials, record NCT07279688. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07279688
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
- NCT number
- NCT07279688
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- University Hospital, Brest
- Conditions
- Polymyalgia Rheumatica (PMR)
- Interventions
- Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg, Placebo 2 mg
- First posted
- 2025-12-12
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Following of the Polymyalgia Rheumatica Activity score | From week 0 to week 24 | Polymyalgia Rheumatica Activity Score (PMR-AS) ≤10 (no flare) without steroids at week 24. The Polymyalgia Rheumatica Activity Score is calculated by combining several parameters (patient's pain assessment (using a visual analogue scale) + physician's global assessment of the disease (using a visual analogue scale)+ morning stiffness + C-Reactive Protein level). If PMR-AS ≤ 1,5 means remission of the disease. If PMR-AS \< 7 means inactive activity of the disease. If 7 \<PMR-AS \< 17 means low activity of the disease. If PMR-AS \> 17 means high activity of the disease. |
| Secondary | Following of the Polymyalgia Rheumatica Activity score | From week 0 to week 12 | Polymyalgia Rheumatica Activity score ≤10 (no flare) without steroids at week 12. The Polymyalgia Rheumatica Activity Score is calculated by combining several parameters (patient's pain assessment (using a visual analogue scale) + physician's global assessment of the disease (using a visual analogue scale)+ morning stiffness + C-Reactive Protein level). If PMR-AS ≤ 1,5 means remission of the disease. If PMR-AS \< 7 means inactive activity of the disease. If 7 \<PMR-AS \< 17 means low activity of the disease. If PMR-AS \> 17 means high activity of the disease. |
| Secondary | Following of the Polymyalgia Rheumatica Activity score | From week 0 to week 36 | Polymyalgia Rheumatica Activity score ≤10 (no flare) without steroids at week 36. The Polymyalgia Rheumatica Activity Score is calculated by combining several parameters (patient's pain assessment (using a visual analogue scale) + physician's global assessment of the disease (using a visual analogue scale)+ morning stiffness + C-Reactive Protein level). If PMR-AS ≤ 1,5 means remission of the disease. If PMR-AS \< 7 means inactive activity of the disease. If 7 \<PMR-AS \< 17 means low activity of the disease. If PMR-AS \> 17 means high activity of the disease. |
| Secondary | Following of the Polymyalgia Rheumatica Activity score | From week 0 to week 36 | Absence of flare according to the investigator at week 36. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07279688
GET https://conductscience.org/api/trials/v1/NCT07279688/registered